Robert W. Buchanan, MD | Psychiatrist.com

Academic Highlights

Switching Antipsychotic Medications to Reduce Adverse Event Burden in Schizophrenia: Establishing Evidence-Based Practice

October 23, 2013

John W. Newcomer, Peter J. Weiden, Robert W. Buchanan

Educational Activity

Novel Pharmacologic Targets for the Treatment of Negative Symptoms in Schizophrenia

May 15, 2013

Robert W. Buchanan

Original Research

Bupropion Sustained Release Added to Group Support for Smoking Cessation in Schizophrenia: A New Randomized Trial and a Meta-Analysis

April 5, 2011

Elaine Weiner, M. Patricia Ball, Alison S. Buchholz, et al

Original Research

A Randomized Double-Blind Trial of Atomoxetine for Cognitive Impairments in 32 People With Schizophrenia

April 7, 2009

Deanna L. Kelly, Robert W. Buchanan, Douglas L. Boggs, et al

Original Research

The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update

November 15, 2007

Troy A. Moore, Robert W. Buchanan, Peter F. Buckley, et al

Letter to the Editor

Reply to "Galantamine and QTc Prolongation"

January 15, 2007

Matthew W. Nelson, Robert W. Buchanan

Letter to the Editor

Galantamine-Induced QTc Prolongation

January 16, 2006

Matthew W. Nelson, Robert W. Buchanan

Original Research

The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2003 Update

April 1, 2004

Alexander L. Miller, Catherine S. Hall, Robert W. Buchanan, et al